Imara to Webcast Conference Call of Third Quarter Financial Results
Imara Inc. (Nasdaq: IMRA) will host a conference call and live webcast on November 5, 2020, at 8:30 a.m. ET to discuss its Q3 2020 financial results and business highlights.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Imara Inc. (Nasdaq: IMRA) will host a conference call and live webcast on November 5, 2020, at 8:30 a.m. ET to discuss its Q3 2020 financial results and business highlights. The company focuses on developing treatments for rare inherited genetic disorders of hemoglobin, including its lead product, IMR-687, a potential disease-modifying treatment for sickle cell disease and beta-thalassemia. Investors can access the webcast on the Imara website, and a replay will be available afterward.
Positive
- Imara is advancing IMR-687, a novel therapeutic targeting sickle cell disease and beta-thalassemia.
- The upcoming conference call aims to provide insights on the company's Q3 2020 financial performance.
Negative
- None.
Details
News Market Reaction – IMRA
The recorded move for IMRA in the trading session of this news was +3.81%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company will host a conference call and live webcast on Thursday, November 5, 2020, at 8:30 a.m. ET to discuss its third quarter 2020 financial results and recent business highlights.
A live webcast will be available under “Events and Presentations” in the Investors section of the company's website at imaratx.com. The conference call can be accessed by dialing +1 (833) 519-1307 (U.S. domestic) or (914) 800-3873 (international) and referring to conference ID 7573255. A replay of the webcast will be archived on the Imara website following the presentation.
About Imara
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types. For more information, please visit www.imaratx.com
Media Contact:
Gina Nugent
Ten Bridge Communications
617-460-3579
gina@tenbridgecommunications.com
Investor Contact:
Michael Gray
617-835-4061
mgray@imaratx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.